Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Receivables (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Receivables for 15 consecutive years, with $2000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Receivables fell 50.0% year-over-year to $2000.0, compared with a TTM value of $2000.0 through Jun 2025, down 50.0%, and an annual FY2024 reading of $5000.0, up 400.0% over the prior year.
  • Receivables was $2000.0 for Q2 2025 at Alaunos Therapeutics, roughly flat from $2000.0 in the prior quarter.
  • Across five years, Receivables topped out at $15.2 million in Q2 2021 and bottomed at $1000.0 in Q4 2023.
  • Average Receivables over 5 years is $2.1 million, with a median of $4000.0 recorded in 2022.
  • The sharpest move saw Receivables soared 540.15% in 2021, then tumbled 99.64% in 2022.
  • Year by year, Receivables stood at $1.1 million in 2021, then crashed by 99.64% to $4000.0 in 2022, then crashed by 75.0% to $1000.0 in 2023, then surged by 400.0% to $5000.0 in 2024, then plummeted by 60.0% to $2000.0 in 2025.
  • Business Quant data shows Receivables for TCRT at $2000.0 in Q2 2025, $2000.0 in Q1 2025, and $5000.0 in Q4 2024.